New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ
Executive Summary
New insulin therapies need to be compared to traditional insulin therapies in studies with regimens that resemble usual clinical practice, the Agency for Healthcare Research and Quality says
You may also be interested in...
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
New Comparative Effectiveness Center Should Ensure Evidence Quality – IOM
The Institute of Medicine says the government can boost the quality and usefulness of comparative effectiveness research by creating a single national program to build on existing efforts